FDA’s regulatory template appears unchanged in the face of new compounding legislation and draft guidance, but the continued enforcement may help bring more facilities into the oversight fold.
In two recent warning letters, the agency used language nearly identical to a letter issued prior to its release of draft guidance outlining enforcement standards under the recently-enacted Drug Quality...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?